Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2071 to 2085 of 8224 results

  1. Gambling

    Awaiting development Reference number: GID-QS10099 Expected publication date: TBC

    Quality standard
    Awaiting development

  2. Prevention of dementia

    Awaiting development Reference number: GID-QS10109 Expected publication date: TBC

    Quality standard
    Awaiting development

  3. Secondary care management of malignant hypertension

    Awaiting development Reference number: GID-QS10107 Expected publication date: TBC

    Quality standard
    Awaiting development

  4. Sleep disordered breathing

    Awaiting development Reference number: GID-QS10096 Expected publication date: TBC

    Quality standard
    Awaiting development

  5. Readmission to ICU within 48hrs

    Awaiting development Reference number: GID-QS10105 Expected publication date: TBC

    Quality standard
    Awaiting development

  6. Primary hyperparathyroidism

    Awaiting development Reference number: GID-QS10089 Expected publication date: TBC

    Quality standard
    Awaiting development

  7. Lenacapavir for preventing HIV-1 in people aged 16 years or older [ID6495]

    In development Reference number: GID-TA11638 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Sacituzumab govitecan with pembrolizumab for untreated metastatic non-small-cell lung cancer with a PD-L1 expression of 50% or more [TSID12280]

    Awaiting development Reference number: GID-TA11880 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Imsamotide with etimumotide and pembrolizumab for untreated unresectable or metastatic melanoma in people 12 years and over [TSID12279]

    Awaiting development Reference number: GID-TA11882 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Pozelimab with cemdisiran for treating symptomatic generalised myasthenia gravis [TSID12287]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  11. School-based interventions: physical and mental health and wellbeing promotion

    In development Reference number: GID-QS10070 Expected publication date: TBC

    Quality standard
    In development

  12. Lanadelumab for preventing recurrent attacks of hereditary angioedema in people 2 years and over [TSID12298]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  13. Cosibelimab for treating advanced cutaneous squamous cell carcinoma when curative surgery or radiotherapy is unsuitable [ID6663]

    Awaiting development Reference number: GID-TA11883 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Obsessive-compulsive disorder and body dysmorphic disorder: assessment and management

    In development Reference number: GID-NG10435 Expected publication date: TBC

    NICE guideline
    In development

  15. Concizumab for treating severe haemophilia A or moderate to severe haemophilia B in people 12 years and over without inhibitors [ID5099]

    Awaiting development Reference number: GID-TA10972 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development